Title

Role Of Neuropeptides In Migraine: Where Do They Stand In The Latest Expert Recommendations In Migraine Treatment?

Keywords

Calcitonin gene-related peptide; Headache; Substance P; Trigeminovascular system

Abstract

Many factors have been implicated in the pathogenesis of migraine headache, including activation of the trigeminovascular system, dysfunction of: cerebral blood vessels, circulating vasoactive substances, mitochondrial energy metabolism, brain oxygenation and metabolism, platelet disorder, alterations in serotonin levels, low levels of brain tissue magnesium, altered transport of ions across the cell membrane, and inheritance and dysfunction of the brainstem periaqueductal gray matter. The headache phase of migraine is associated with cerebral vasodilation and inflammation, presumably mediated by the release of vasoactive substances and neuropeptides including CGRP (calcitonin gene-related peptide). Increased serum CCRP levels have been detected during migraine and cluster headache. One strategy to treat migraine is to inhibit the release of neuropeptides or to block their receptors. This article briefly reviews some experimental and clinical investigations focused on neuropeptide involvement in migraine. © 2007 Wiley-Liss, Inc.

Publication Date

9-1-2007

Publication Title

Drug Development Research

Volume

68

Issue

6

Number of Pages

294-314

Document Type

Review

Personal Identifier

scopus

DOI Link

https://doi.org/10.1002/ddr.20193

Socpus ID

38149102414 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/38149102414

This document is currently not available here.

Share

COinS